key: cord-1003852-uaw0j7gq authors: Manisty, C.; Treibel, T. A.; Jensen, M.; Joy, G.; Gupta, R. K.; Cutino-Moguel, M.-T.; Andiapen, M.; Jones, J.; Taylor, S.; Otter, A.; Pade, C.; Gibbons, J. M.; Lee, W. Y. J.; Jones, M.; Williams, D. M.; Lambourne, J.; Fontana, M.; COVIDsortium Investigators,; Altmann, D. M.; Boyton, R.; Maini, M. K.; McKnight, A.; Brooks, T.; Chain, B.; Noursadeghi, M.; Moon, J. C. title: Characterising heterogeneity and sero-reversion in antibody responses to mild SARS-CoV-2 infection: a cohort study using time series analysis and mechanistic modelling date: 2020-11-06 journal: nan DOI: 10.1101/2020.11.04.20225920 sha: 858025afd11f8bfd856ca988c7587d0356982966 doc_id: 1003852 cord_uid: uaw0j7gq Background SARS-CoV-2 serology is used to identify prior infection at individual and at population level. Extended longitudinal studies with multi-timepoint sampling to evaluate dynamic changes in antibody levels are required to identify the time horizon in which these applications of serology are valid, and to explore the longevity of protective humoral immunity. Methods Health care workers were recruited to a prospective cohort study from the first SARS-CoV-2 epidemic peak in London, undergoing weekly symptom screen, viral PCR and blood sampling over 16-21 weeks. Serological analysis (n=12,990) was performed using semi quantitative Euroimmun IgG to viral spike S1 domain and Roche total antibody to viral nucleocapsid protein (NP) assays. Comparisons were made to previously reported pseudovirus neutralising antibody measurements. Findings A total of 157/729 (21.5%) participants developed positive SARS-CoV-2 serology by one or other assay, of whom 31.0% were asymptomatic and there were no deaths. Peak Euroimmun anti-S1 and Roche anti-NP measurements correlated (r=0.57, p<0.0001) but only anti S1 measurements correlated with near contemporary pseudovirus neutralising antibody titres (measured at 16-18 weeks, r=0.57, p<0.0001). By 21 weeks of follow-up, 31/143 (21.7%) anti S1 and 6/150 (4.0%) anti-NP measurements reverted to negative. Mathematical modelling suggested faster clearance of anti-S1 compared to anti NP (median half-life of 2.5 weeks versus 4.0 weeks), earlier transition to lower levels of antibody production (median of 8 versus 13 weeks), and greater reductions in relative antibody production rate after the transition (median of 35% versus 50%). Interpretation Mild SARS CoV 2 infection is associated with heterogenous serological responses in Euroimmun anti-S1 and Roche anti-NP assays. Anti-S1 responses showed faster rates of clearance, more rapid transition from high to low level production rate and greater reduction in production rate after this transition. The application of individual assays for diagnostic and epidemiological serology requires validation in time series analysis. Evidence before this study 65 We searched PubMed, medRxiv, and bioRxiv for ["antibody" OR "serology"] AND ["SARS-CoV-2" OR 66 "COVID-19"]. The available literature highlights widespread use of serology to detect recent SARS-67 CoV-2 infection in individual patients and in population epidemiological surveys. Antibody to virus 68 spike protein S1 domain is widely reported to correlate with neutralising antibody titres. The existing 69 assays have good sensitivity to detect seroconversion within 14 days of incident infection, but the 70 available longitudinal studies have reported variable rates of decline in antibody levels and reversion 71 to undetectable levels in some people over 3 months. High frequency multi-time point serology data 72 for different antibody targets or assays in longitudinal cohorts from the time of incident infection to 73 greater than 3 months follow up are lacking. 74 We combine detailed longitudinal serology using the Euroimmun anti-S1 and Roche anti-nucleocapsid 76 protein (NP) assays in 731 health care workers from the time of the first SARS-CoV-2 epidemic peak 77 in London, UK. In 157 seroconverters (using either assay) we show substantial heterogeneity in 78 semiquantitative antibody measurements over time between individuals and between assays. 79 Mathematical modelling of individual participant antibody production and clearance rates in individuals 80 with at least 8 data points over 21 weeks showed anti-S1 antibodies to have a faster clearance rate, 81 earlier transition from the initial antibody production rate to lower rates, and greater reduction in 82 antibody production rate after this transition, compared to anti-NP antibodies as measured by these 83 assays. As a result, Euroimmun anti-S1 measurements peaked earlier and then reduced more rapidly 84 than Roche anti-NP measurements. In this study, these differences led to 21% anti-S1 sero-reversion, 85 compared to 4% anti-NP sero-reversion over 4-5 months. 86 Detection of antibodies to SARS-CoV-2 is key to establishing the prevalence of infection in the 95 population, and hence tracking the progress of the pandemic, and may be used to diagnose past 96 infection in individual patients. Moreover, antibody to envelope spike protein may contribute to 97 protective immunity. 1-4 Interpretation of cross-sectional serology is critically dependent on 98 understanding the dynamics of the antibody response, and how this might vary for different viral target 99 antigens, in different assays and between individuals. 100 Numerous studies have shown that individuals with a confirmed polymerase chain reaction (PCR) 101 diagnosis of SARS-CoV-2 develop IgM, IgA and IgG against the spike protein S1 domain and 102 nucleocapsid protein (NP) within 2 weeks of symptom onset, which remain detectable following initial 103 viral clearance. [5] [6] [7] Early data suggest antibody levels correlate with disease severity. 8, 9 Antibody 104 responses to other human coronaviruses decay over time with regular reinfection events, which has 105 caused concern that SARS-CoV-2 immunity following natural infection may be short-lived, leading to 106 risk of re-infection and making the possibility for achieving herd immunity through natural infection 107 unrealistic. [10] [11] [12] The data for SARS-COV-2 remains conflicting, with some longitudinal serological 108 studies suggesting rapid antibody decline, while others have shown much greater persistence. These vary by cohort (hospital, symptomatic only, PCR positive, community), assay (quality-assured, 110 antigen target), sampling granularity and follow-up period. 111 We present a detailed temporal analysis of circulating antibody using two widely used 112 semi-quantitative commercial assays to detect either anti-S1 or anti-NP in a cohort of hospital health 113 care workers in a prospective longitudinal multi-centre cohort study with high frequency serial 114 sampling over 16-21 weeks during the first epidemic wave in London, UK. We assessed concordance 115 between assays and the determinants of inter-individual heterogeneity in antibody responses by 116 testing associations with clinical and demographic variables. Finally, we applied mathematical 117 modelling to infer the fundamental mechanisms that may underpin changes to antibody levels over 118 Methods 120 The study was approved by a UK Research Ethics Committee (South Central -Oxford A Research 122 Ethics Committee, reference 20/SC/0149). The details of participant screening, study design, sample 123 collection, and sample processing are previously published and registered on ClinicalTrials.gov, 124 NCT04318314. 23 Briefly, hospital healthcare workers (HCWs) self-declared fit to attend work were 125 recruited to an observational cohort study consisting of questionnaires and biological sample 126 collection at baseline and over 16 weekly-follow-up visits. Those who were unable to attend follow-up 127 visits were consulted remotely to enable capture of information regarding possible exposures and 128 symptoms. The baseline questionnaire included demographic data, medical history and exposures, 129 alongside detailed information regarding the nature and timing of self-reported symptoms over the 130 preceding 3 months. 23 Follow-up weekly questionnaires included data on new symptoms and changes 131 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 6, 2020. ; https://doi.org/10.1101/2020.11.04.20225920 doi: medRxiv preprint to occupational and community risk factors, or results of tests conducted outside of the study. 132 Symptoms were classified as follows: 'case-defining' (fever, new dry cough or a new loss of taste or 133 smell; which have been shown to predict COVID-19 positivity with high specificity), 'non-specific 134 (symptoms other than case-defining symptoms), or asymptomatic (no symptoms reported throughout 135 the study period or in the three preceding months). week follow-up of Cohort 2. Towards the end of the study period for Cohort 2 (follow-up weeks 12-15) 143 following the decline in community infection rates, the frequency of blood sampling was reduced to 144 twice per month rather than weekly, in order to improve tolerability to participants. 145 Nasal RNA stabilizing swabs for molecular testing for SARS-CoV-2 were acquired at baseline and 147 weekly. RT-PCR was performed on nasal swabs using Roche cobas® SARS-CoV-2 test. SARS-CoV-148 2 antibody testing was performed in a single laboratory at Public Health England on all available 149 serum samples from baseline and follow-up visits using two commercial assays according to 150 manufacturers' protocols. These were the Euroimmun anti-SARS-CoV-2 enzyme-linked 151 immunosorbent assay (ELISA) (IgG) targeting IgG specific for the SARS-CoV-2 S1 antigen, and the 152 Roche Elecsys Anti-SARS-CoV-2 electrochemiluminescence immunoassay (ECLIA) that detects 153 antibodies (including IgG) directed against the SARS-CoV-2 nucleocapsid protein (NP). 24-27 154 The Euroimmun ELISA was performed using a Stratec Gemini automated microplate processor as 155 previously described. 28 Raw optical density (OD) readings were adjusted by calculating the ratio of the 156 OD of the control or participant sample divided by the OD of the assay calibrator. A ratio (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 6, 2020. ; https://doi.org/10.1101/2020.11.04.20225920 doi: medRxiv preprint In descriptive analyses, Spearman's rank correlation coefficients were calculated for all paired assay 169 values across the study period. Univariable associations of demographics, symptoms and exposures 170 with serostatus (seropositivity by one or both antibody assays at any timepoint) were assessed using 171 logistic regression. Univariable and multivariable associations of characteristics (including age, sex, 172 ethnicity and case-defining symptom status) with peak antibody levels were also quantified using 173 linear regression for anti-N IgG/IgM and anti-S1 IgG. 174 We also performed univariable and multivariable survival analyses to assess whether participant 175 characteristics (including age, sex, ethnicity, case-defining symptom status and peak anti-S1) were 176 associated with time to sero-reversion for the anti-S1 assay. For this analysis, we included all 177 participants who seroconverted on the anti-S1 assay at any point during follow-up. We assumed 178 synchronous onset of infection for these individuals by indexing the start time for the survival analysis 179 as the first week of Cohort 1 study enrolment (the week of UK lockdown). Anti-S1 sero-reversion was 180 defined as a negative test in the last assay performed during follow-up for each participant. 181 Participants who sero-reverted exited the survival analysis on the first week where a negative test 182 (following an earlier positive test) was recorded; those who did not sero-revert were censored on the 183 week of their last available anti-S1 serology result. Analyses were conducted in R (version 3.6.3) and 184 Stata Statistical Software version 16 (College Station, TX, USA). 185 Circulating antibody levels are determined by the balance between rates of production and clearance. 187 We represented antibody production by a simplified discrete mechanistic model captured by 188 equation 1, with time indexed to calendar weeks from initiation of UK lockdown (as described for the 189 survival analyses). We incorporated a production rate (AbPr) and an antibody turnover (clearance 190 rate, r). Antibody production was simplified to two phases, an initial high rate (AbPr1) followed by a 191 switch to a lower rate (AbPr2), after a time t_stop. Since the assay units of antibody concentration are 192 arbitrary and are not comparable between assays, the value of AbPr 1 is also arbitrary, and serves 193 only to scale the model output to the scale of the data. AbPr2 is expressed as a proportion of AbPr1. 194 The rate of clearance r can be directly calculated from the half-life, which was allowed to vary 195 between 1 week and 4 weeks (the latter equivalent to the known turnover rate of free IgG). An 196 important emerging feature of the model is that the time to plateau (peak) is determined only by the 197 clearance rate (Supplementary Figure 2) , and not by the rate of production AbPr1. Furthermore, any 198 subsequent fall from the peak must reflect a corresponding decrease in AbPr. Hence the model 199 assumption that AbPr2<-AbPr1. 200 Equation 1: Ab t = Ab t-1 + AbPr -Ab t-1 * (1 -e -rt ), where t is time in weeks, AbPr = AbPr 1 for 1 < t < 201 t_stop or AbPr 2 for t_stop < t < t_end; and AbPr2